Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281253143> ?p ?o ?g. }
- W4281253143 endingPage "632" @default.
- W4281253143 startingPage "632" @default.
- W4281253143 abstract "In today’s global plan to completely eradicate hepatitis C virus (HCV), the essential list of medications used for HCV treatment are direct-acting antivirals (DAAs), as interferon-sparing regimens have become the standard-of-care (SOC) treatment. HCV nonstructural protein 5A (NS5A) inhibitors are a very common component of these regimens. Food and Drug Administration (FDA)-approved NS5A inhibitors, although very potent, do not have the same potency against all eight genotypes of HCV. Therefore, this study aims to synthesize NS5A inhibitor analogues with high potency pan-genotypic activity and high metabolic stability. Starting from an NS5A inhibitor scaffold previously identified by our research group, we made several modifications. Two series of compounds were created to test the effect of changing the length and spatial conformation (para-para vs. meta-meta-positioned bis-imidazole-proline-carbamate), replacing amide groups in the linker with imidazole groups, as well as different end-cap compositions and sizes. The frontrunner inhibits genotype 1b (Con1) replicon, with an EC50 value in the picomolar range, and showed high genotypic coverage with nanomolar range EC50 values against four more genotypes. This together with its high metabolic stability (t½ > 120 min) makes it a potential preclinical candidate." @default.
- W4281253143 created "2022-05-23" @default.
- W4281253143 creator A5013295233 @default.
- W4281253143 creator A5015665201 @default.
- W4281253143 creator A5020850548 @default.
- W4281253143 creator A5022346445 @default.
- W4281253143 creator A5024479909 @default.
- W4281253143 creator A5044505779 @default.
- W4281253143 creator A5073733931 @default.
- W4281253143 creator A5081783897 @default.
- W4281253143 creator A5082528019 @default.
- W4281253143 creator A5086920605 @default.
- W4281253143 date "2022-05-20" @default.
- W4281253143 modified "2023-09-30" @default.
- W4281253143 title "Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors" @default.
- W4281253143 cites W1574994167 @default.
- W4281253143 cites W178187152 @default.
- W4281253143 cites W1887624773 @default.
- W4281253143 cites W1975293246 @default.
- W4281253143 cites W1986981517 @default.
- W4281253143 cites W1989027571 @default.
- W4281253143 cites W1993681618 @default.
- W4281253143 cites W1996935441 @default.
- W4281253143 cites W2014290325 @default.
- W4281253143 cites W2021199098 @default.
- W4281253143 cites W2029831892 @default.
- W4281253143 cites W2030439961 @default.
- W4281253143 cites W2043509228 @default.
- W4281253143 cites W2043976325 @default.
- W4281253143 cites W2049322739 @default.
- W4281253143 cites W2051060071 @default.
- W4281253143 cites W2061583504 @default.
- W4281253143 cites W2064285218 @default.
- W4281253143 cites W2068672372 @default.
- W4281253143 cites W2071911570 @default.
- W4281253143 cites W2075095707 @default.
- W4281253143 cites W2078374001 @default.
- W4281253143 cites W2090155417 @default.
- W4281253143 cites W2090431249 @default.
- W4281253143 cites W2090996511 @default.
- W4281253143 cites W2116694893 @default.
- W4281253143 cites W2119010298 @default.
- W4281253143 cites W2119571917 @default.
- W4281253143 cites W2122717211 @default.
- W4281253143 cites W2125422626 @default.
- W4281253143 cites W2125792789 @default.
- W4281253143 cites W2129069648 @default.
- W4281253143 cites W2130479394 @default.
- W4281253143 cites W2134967712 @default.
- W4281253143 cites W2135732933 @default.
- W4281253143 cites W2155430111 @default.
- W4281253143 cites W2158519211 @default.
- W4281253143 cites W2160891250 @default.
- W4281253143 cites W2169678694 @default.
- W4281253143 cites W2176516200 @default.
- W4281253143 cites W2296575546 @default.
- W4281253143 cites W2411964236 @default.
- W4281253143 cites W2565050364 @default.
- W4281253143 cites W2591108500 @default.
- W4281253143 cites W2593608883 @default.
- W4281253143 cites W2594237269 @default.
- W4281253143 cites W2742081931 @default.
- W4281253143 cites W2776901446 @default.
- W4281253143 cites W2790029625 @default.
- W4281253143 cites W2799528434 @default.
- W4281253143 cites W2809785330 @default.
- W4281253143 cites W2883877962 @default.
- W4281253143 cites W2891803865 @default.
- W4281253143 cites W2954772469 @default.
- W4281253143 cites W2954822763 @default.
- W4281253143 cites W2982819257 @default.
- W4281253143 cites W2986112962 @default.
- W4281253143 cites W3009933136 @default.
- W4281253143 cites W3011817381 @default.
- W4281253143 cites W3012932628 @default.
- W4281253143 cites W3022715365 @default.
- W4281253143 cites W3044388665 @default.
- W4281253143 cites W3168436232 @default.
- W4281253143 cites W3200721863 @default.
- W4281253143 cites W3210601840 @default.
- W4281253143 cites W4200497834 @default.
- W4281253143 cites W4205632467 @default.
- W4281253143 cites W4211014289 @default.
- W4281253143 cites W4211051574 @default.
- W4281253143 cites W4248107770 @default.
- W4281253143 cites W52227263 @default.
- W4281253143 cites W891543994 @default.
- W4281253143 doi "https://doi.org/10.3390/ph15050632" @default.
- W4281253143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35631457" @default.
- W4281253143 hasPublicationYear "2022" @default.
- W4281253143 type Work @default.
- W4281253143 citedByCount "2" @default.
- W4281253143 countsByYear W42812531432023 @default.
- W4281253143 crossrefType "journal-article" @default.
- W4281253143 hasAuthorship W4281253143A5013295233 @default.
- W4281253143 hasAuthorship W4281253143A5015665201 @default.
- W4281253143 hasAuthorship W4281253143A5020850548 @default.
- W4281253143 hasAuthorship W4281253143A5022346445 @default.